Refine by
Patient Testing Articles & Analysis
121 news found
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to ...
ByTempus
We are thrilled to announce that Vantage, has successfully passed NHS England’s rigorous LFPSE (Learning from Patient Safety Events) compliance testing and are officially recognised as an accredited LFPSE supplier. This accreditation is a testament to our commitment to enhancing patient safety in healthcare organisations across the nation. ...
Therefore, it is important to assess the patient's physical condition and possible risk of complications prior to treatment. ...
In both study arms, patients had BVA testing within a day of admission and one day prior to discharge, along with physician assessment for congestion. ...
Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of BVA-guided care on decongestion therapy and outcomes versus standard of care. In both study arms, patients had BVA testing within a day of admission and one day prior to discharge, along with physician assessment for congestion. ...
We advise patients to get tested for ESR1 mutations at progression in their metastatic treatment, so that their healthcare team can identify the right treatment options for their ...
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. ...
In fact, the disease is responsible for “two million broken bones and $19 billion in related costs every year”, while by the year 2025, “experts predict that osteoporosis will be responsible for approximately three million fractures and $25.3 billion in costs annually.” Sadly, most patients are not aware of having the condition before suffering from a ...
Through APCaRI, the Lewis team established a patient data registry and biorepository that has grown into one of the largest prostate cancer databases in the world. ...
Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET -AML test for early detection of acute myeloid leukemia (AML) in ...
VisionQuest Biomedical founder and CEO Peter Soliz (PhD) has just been awarded a $1 million Commercialization Readiness Pilot Program (CRP) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (part of the US National Institutes of Health) for his work on early detection of DPN. With the support of this grant, Dr. Soliz will develop a commercial prototype and seek FDA ...
Labs and outpatient sites employ phlebotomists who collect blood samples through venipuncture, a process that is physically and psychologically uncomfortable for many. In addition to these barriers, test results can be difficult to understand. Patients get their blood testing done and then have to see their provider again to review results that ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting – which ...
All users can extract and tailor patient-specific clinical interpretation reports online thanks to the secure, cloud-based software tools and proprietary biomarker database. ...
” The single-centre, BENEFIT-APDT open-label study was carried out at HCA Healthcare’s Memorial Health University Medical Center in Savannah, Georgia. A total of 319 pre-surgical patients were enrolled and tested for the presence of S. aureus in the nose. Patients were then treated with a single, 5-minute nasal photodisinfection ...
These specialists will be able to run rapid amyloid status tests on patients during their regular clinical evaluations and then deliver automated same-day results. ...
Last month the company announced that miR Sentinel™ Prostate Cancer Test is commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. ...
The Company is continuing to make progress to initiate clinical sites in Europe through oncology networks, potentially including networks in Germany, Spain, and France. Following site activation, patients will be screened, tested for HLA type, randomized, and enrolled into any of 3 clinical trial arms, and treatment of the first patients will ...
About SEngine Precision Medicine SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures utilizing patient specific tumor cells. ...
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. ...